they are still lost in their own world, but they sure are good at doling out more shares at the expense of the shareholders, why does management refuse to BUY shares if things are so great??????????????????????
As usual, I request that this ONE topic be kept free of insults, short-term price forecasts and similar contentious stuff.
I missed a few minutes in the middle of the Q&A. My impressions of highlights:
Well, a lowlight first: they seem to be hardening into a pattern of saying that there is about to be something good coming out that they can't give specifics for right now. TERRIBLE HORRIBLE habit to get into. Maybe do it once every other year. I don't want to hear that '110 looks more interesting than expected. I don't want to hear that there's something to say about ruxo and marrow structure. When you're talking pipeline, don't just say that there's stuff you may be able to talk about soon. [takes a couple deep breaths]
I LOVE the free titration doses thing. Yea, as an analyst said it COULD be seen as a 2 week free sample, but that's not so bad either.
Definitely got the impression that they'd been over the PML case with FDA and were told not to comment on likely degree of association. That isn't as good as could be hoped for, but there's no sign that FDA is treating it as alarming, either.
Presentation quality is important for Incyte. This one was just adequate. The presenters didn't get rattled, but they didn't seem well prepared, either.
Putting all that in writing, I guess I have to call it a so-so CC reporting a good (maybe even very good) quarter.
Hi Guys ..
Intelgenx launched their first drug Forfivo in October this will drive Intelgenx into Profitability this Year because of its very low burn-rate of around $1.2 Mil a year !
IGXT Submits NDA for Anti-Migraine Versafilm to FDA in March another 1x NDA filing for Erectile Dysfunction Versafilm and 2x ANDA filings expected in 1H 2013. Two Partnerships for Anti-Migraine and Erectile Dysfunction products is expected in 1H 2013 too which means more Cash for Intelgenx .Intelgenx has 9x Drugs in late stage which will be all on the Market within next 2-3 years .
IGXT has NO DEBT and Cash untill 2016 means enough to drive this Company into Profitability which is expected for this Year . Current Market Cap of just $31 M is really Brutally Underpriced .
IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Market Cap : $31 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year
Price : $0.63
Shares Out : 50 M ( 20 M shares are held by Insiders & Institutions)
March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.